On Friday, the US Food and Drug Administration (FDA) approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer. “Today’s approval marks the first oral drug in this class and it may eliminate some patients’ need to visit the clinic for treatments that require administration by a healthContinue Reading